デフォルト表紙
市場調査レポート
商品コード
1526336

がん/ 腫瘍プロファイリングの世界市場

Cancer / Tumor Profiling


出版日
ページ情報
英文 376 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
がん/ 腫瘍プロファイリングの世界市場
出版日: 2024年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 376 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

がん/ 腫瘍プロファイリングの世界市場は2030年までに198億米ドルに達する見込み

2023年に103億米ドルと推定されるがん/ 腫瘍プロファイリングの世界市場は、2023年から2030年にかけてCAGR 9.8%で成長し、2030年には198億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである免疫測定技術は、CAGR 9.3%を記録し、分析期間終了時には62億米ドルに達すると予測されます。次世代シークエンシング技術分野の成長率は、分析期間中CAGR 10.8%と推定されます。

米国市場は37億米ドルと推定、中国はCAGR10.6%で成長予測

米国のがん/ 腫瘍プロファイリング市場は、2023年に37億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは10.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.7%と9.2%と予測されています。欧州では、ドイツがCAGR約9.9%で成長すると予測されています。

世界のがん/ 腫瘍プロファイリング市場- 主要動向と促進要因のまとめ

ゲノミクスと次世代シーケンシング(NGS)による分子プロファイリングの登場は、個別化がん治療に革命をもたらしています。組織サンプルや侵襲性の低いリキッドバイオプシーを使用することで、分子プロファイリングは個別化がん治療に極めて重要な遺伝子変異や融合を同定します。近年、ホルマリン固定パラフィン包埋(FFPE)組織に対するDNA/RNAシーケンスの適用により、腫瘍内の作用標的をピンポイントで特定する能力が著しく向上しました。とはいえ、治療可能な標的があったとしても、それが必ずしも疾患の進行や臨床効果に関与しているとは限らないです。効果的な分子プロファイリングには、高度な技術力と腫瘍生物学および関連治療に対する深い理解が必要であり、特にNGSが代替治療の選択肢を提供するような標準化された治療法がない場合にはなおさらです。

腫瘍プロファイリングは、がんの遺伝的背景に関する包括的な洞察を提供し、特定の遺伝子変化を標的とした標的療法の開発を促進します。このアプローチは肺がんの治療を著しく変え、EGFR変異を標的とした治療法は最も早い成功例のひとつです。プロファイリングは、個々の変異をピンポイントで特定するだけでなく、がんの進行と耐性メカニズムのより広範な分子的枠組みを解明し、耐性と闘うための併用療法への道を開く。さらに、プロファイリングによるバイオマーカーの同定は、免疫療法に対する患者の反応を予測し、より個別化された治療レジメンを可能にします。ctDNAやCTC解析のようなリキッドバイオプシー技術の統合は、プロファイリング能力をさらに増強し、腫瘍動態や微小残存病変の非侵襲的リアルタイムモニタリングを可能にします。

がん/腫瘍プロファイリング市場の成長は、分子プロファイリング技術の進歩、リキッドバイオプシーの採用拡大、AIと機械学習の統合など、いくつかの要因によってもたらされます。シングルセルシーケンス技術の開発は、腫瘍の不均一性に関する詳細な洞察を提供し、疾患の進行や治療抵抗性を引き起こす亜集団を特定します。このレベルの詳細な情報は、より効果的な治療戦略の構築をサポートします。さらに、AIとMLは複雑な分子データの解析を強化し、プロファイリングの精度を向上させ、患者の転帰の予測を可能にします。これらの技術の能力の拡大と臨床への統合により、より個別化された、より迅速ながん治療が期待され、最終的には患者の転帰の改善と腫瘍学の継続的な革新につながります。

調査対象企業の例(注目の全55社)

  • Caris Life Sciences
  • Genomic Health, Inc.
  • Helomics Corporation
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Nanostring Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • Oxford Gene Technology
  • Qiagen NV
  • Ribomed Biotechnologies, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP10868

Global Cancer / Tumor Profiling Market to Reach US$19.8 Billion by 2030

The global market for Cancer / Tumor Profiling estimated at US$10.3 Billion in the year 2023, is expected to reach US$19.8 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2023-2030. Immunoassays Technology, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$6.2 Billion by the end of the analysis period. Growth in the Next Generation Sequencing Technology segment is estimated at 10.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 10.6% CAGR

The Cancer / Tumor Profiling market in the U.S. is estimated at US$3.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.9% CAGR.

Global Cancer / Tumor Profiling Market - Key Trends & Drivers Summarized

The advent of molecular profiling, driven by genomics and next-generation sequencing (NGS), is revolutionizing personalized cancer treatment. By using tissue samples and less invasive liquid biopsies, molecular profiling identifies genetic mutations and fusions that are crucial for personalized cancer therapies. In recent years, the application of DNA/RNA sequencing on formalin-fixed, paraffin-embedded (FFPE) tissues significantly enhanced the ability to pinpoint actionable targets within tumors. Nevertheless, having a druggable target does not necessarily ensure its role in disease progression or clinical efficacy. Effective molecular profiling necessitates advanced technical skills and a profound understanding of tumor biology and associated therapies, especially in cases lacking standardized treatments where NGS provides alternative therapeutic options.

Tumor profiling offers comprehensive insights into the genetic landscape of cancers, facilitating the development of targeted therapies aimed at specific genetic alterations. This approach notably transformed the treatment of lung cancer, with therapies targeting EGFR mutations being among the earliest successful examples. Beyond pinpointing individual mutations, profiling elucidates the broader molecular framework of cancer progression and resistance mechanisms, paving the way for combination therapies to combat resistance. Additionally, the identification of biomarkers through profiling can predict patient responses to immunotherapy, enabling more personalized treatment regimens. The integration of liquid biopsy techniques, such as ctDNA and CTC analysis, further augments profiling capabilities, allowing non-invasive, real-time monitoring of tumor dynamics and minimal residual disease.

The growth in the cancer/tumor profiling market is driven by several factors, including advancements in molecular profiling technologies, increased adoption of liquid biopsies, and the integration of AI and machine learning. The development of single-cell sequencing technologies offers granular insights into tumor heterogeneity, identifying subpopulations driving disease progression and therapy resistance. This level of detail supports the creation of more effective treatment strategies. Moreover, AI and ML enhance the analysis of complex molecular data, improving the accuracy of profiling and enabling the prediction of patient outcomes. The expanding capabilities of these technologies, combined with their integration into clinical practice, promise more personalized and responsive cancer treatments, ultimately leading to better patient outcomes and continuous innovation in oncology.

Select Competitors (Total 55 Featured) -

  • Caris Life Sciences
  • Genomic Health, Inc.
  • Helomics Corporation
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Nanostring Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • Oxford Gene Technology
  • Qiagen NV
  • Ribomed Biotechnologies, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Rise in Cancer Incidence Fosters Growth in Cancer / Tumor Profiling Market
    • Select Cancer Statistics
    • Total Number of New Cancer Cases by Type: 2022
    • Total Number of Cancer Deaths by Type: 2022
    • Cancer Incidence by Region: 2022
    • Cancer Mortality by Region: 2022
    • Tumor Profiling: At Zenith of Efforts to Expedite Transition from Histologic to Precision Cancer Treatment
    • Economic Frontiers: Trends, Trials & Transformations
    • In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
    • All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
    • With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
    • Global Market Analysis and Prospects
    • Global Cancer/Tumor Profiling Market Looks Forward to Prolific Growth
    • Genomic Profiling, NGS, Breast Cancer & Research: Thriving Segments of Cancer/Tumor Profiling Market
    • NGS as Primary Technology Segment
    • Breast Cancer & Pharmaceutical Segments to Exhibit Solid Gains
    • Research Rules while Treatment Selection Posts Fastest Growth
    • North America Clinches Commanding Stake on Global Cancer/Tumor Profiling Market
    • Asia-Pacific Emerges as Lucrative Market
    • Pulsating Trends Favoring Expansion of Cancer/Tumor Profiling Market
    • Select Market Drivers
    • Market Opportunities
    • Competitive Landscape: Innovation and R&D Focus amid Fierce Competition
    • Cancer / Tumor Profiling - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Molecular Profiling Paves the Way for Personalized Cancer Treatment
    • Introduction of Tumour Profiling Techniques Ensures Timely Treatment for Cancer Patients
    • Application of Cancer/Tumor Profiling in Cancer Research Sees Significant Growth
    • Transformative Advances in Tumor Profiling Technologies Revolutionize Cancer Treatment
    • Liquid Biopsy: A Transformative Tool in Cancer Profiling, Diagnostics, and Monitoring
    • Precision Oncology Holds Upside Potential with Advancements in Multi-Omics Tumor Profiling
    • Leveraging AI and Machine Learning in Tumor Profiling Facilitates Cancer Care
    • Precision Oncology Holds Upside Potential with Advancements in Multi-Omics Tumor Profiling
    • Single-Cell Sequencing: Revolutionizing Cancer Research
    • Tumor Profiling: A Catalyst for Precision Companion Diagnostics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cancer / Tumor Profiling Market Analysis of Annual Sales in US$ Million for Years 2017 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cancer / Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 4: World 13-Year Perspective for Cancer / Tumor Profiling by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2017, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 7: World 13-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 10: World 13-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for In-Situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for In-Situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 13: World 13-Year Perspective for In-Situ Hybridization by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 16: World 13-Year Perspective for Polymerase Chain Reaction by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 19: World 13-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 22: World 13-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 25: World 13-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 28: World 13-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 31: World 13-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 34: World 13-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 37: World 13-Year Perspective for Melanoma Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 40: World 13-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 43: World 13-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 46: World 13-Year Perspective for Clinical Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 49: USA 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 52: USA 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 55: USA 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 58: Canada 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 61: Canada 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 64: Canada 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • JAPAN
    • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 67: Japan 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 70: Japan 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 73: Japan 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • CHINA
    • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 76: China 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 79: China 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 82: China 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • EUROPE
    • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Cancer / Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 85: Europe 13-Year Perspective for Cancer / Tumor Profiling by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2017, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 88: Europe 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 91: Europe 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 94: Europe 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • FRANCE
    • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 97: France 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 100: France 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 103: France 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • GERMANY
    • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 106: Germany 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 109: Germany 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 112: Germany 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • ITALY
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 115: Italy 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 118: Italy 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 121: Italy 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • UNITED KINGDOM
    • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 122: UK Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 124: UK 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 127: UK 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 130: UK 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 133: Rest of Europe 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 136: Rest of Europe 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • ASIA-PACIFIC
    • Cancer / Tumor Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 142: Asia-Pacific 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 145: Asia-Pacific 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030
  • REST OF WORLD
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Cancer / Tumor Profiling by Technology - Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 151: Rest of World 13-Year Perspective for Cancer / Tumor Profiling by Technology - Percentage Breakdown of Value Revenues for Immunoassays, Next Generation Sequencing, In-Situ Hybridization, Polymerase Chain Reaction, Mass Spectrometry and Other Technologies for the Years 2017, 2024 & 2030
    • TABLE 152: Rest of World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of World Historic Review for Cancer / Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 154: Rest of World 13-Year Perspective for Cancer / Tumor Profiling by Cancer Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2017, 2024 & 2030
    • TABLE 155: Rest of World Recent Past, Current & Future Analysis for Cancer / Tumor Profiling by Application - Research Application and Clinical Application - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of World Historic Review for Cancer / Tumor Profiling by Application - Research Application and Clinical Application Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2017 through 2022 and % CAGR
    • TABLE 157: Rest of World 13-Year Perspective for Cancer / Tumor Profiling by Application - Percentage Breakdown of Value Revenues for Research Application and Clinical Application for the Years 2017, 2024 & 2030

IV. COMPETITION